The DOI matches its Crossref record; the references it cites are not checked yet.
Weight loss and risk reduction of obesity-related outcomes in 0·5 million people: evidence from a UK primary care database
Open accessAbstract
High body mass index (BMI) is known to be associated with various conditions, including type 2 diabetes (T2D), osteoarthritis, cardiovascular disease (CVD) and sleep apnoea; however, the impact of intentional weight loss on the risk of these and other outcomes is not well quantified. We examined the effect of weight loss on ten selected outcomes in a population from the UK Clinical Practice Research Datalink (CPRD) GOLD database. Included individuals were >18 years old at the index date (first BMI value between January 2001 and December 2010). They were categorised by their weight pattern between year 1 post-index and year 4 post-index (baseline period) as having stable weight (−5% to +5%) or weight loss (−25% to −10%, plus evidence of intervention or dietary advice to confirm intention to lose weight). For inclusion, individuals also required a BMI of 25.0–50.0 kg/m 2 at the start of the follow-up period, during which the occurrence of ten obesity-related outcomes was recorded. Cox proportional hazard models adjusted for BMI, comorbidities, age, sex and smoking status were used to estimate relative risks for weight loss compared with stable weight. Individuals in the weight-loss cohort had median 13% weight loss. Assuming a BMI of 40 kg/m 2 before weight loss, this resulted in risk reductions for T2D (41%), sleep apnoea (40%), hypertension (22%), dyslipidaemia (19%) and asthma (18%). Furthermore, weight loss was associated with additional benefits, with lower risk of T2D, chronic kidney disease, hypertension and dyslipidaemia compared with maintaining the corresponding stable lower BMI throughout the study. This study provides objective, real-world quantification of the effects of weight loss on selected outcomes, with the greatest benefits observed for the established CVD risk factors T2D, hypertension and dyslipidaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Symptomatic improvements can be achieved with bodyweight reductions of 5-15% for most of these conditions.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Symptomatic improvements can be achieved with bodyweight reductions of 5-15% for most of these conditions.74”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While 5–10% body weight loss in individuals with overweight or obesity has been shown to reduce obesity-related complications, weight loss of ≥15% can further improve risk factors for cardiometabolic disease and improve health-related quality of life [4,5].”
From Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, also taking into account the close association of MASLD, type 2 diabetes and cardiovascular disease, weight loss beneficially modulated blood pressure, lipid profile, glycemia, insulin resistance as well as inflammation [50] and subsequently reduced premature cardiovascular and overall mortality in people with obesity [51].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 32 · Cited by 199
Research works printed but not linked: 1
- OECD Health Policy Study. The heavy burden of obesity. 2019. https://www.oecd-ilibrary.org/docserver/67450d67-en.pdf?expires=1587545422&id=id&accname=guest&checksum=42A754049C8DD63B680DB0EC4EB5DC80. Accessed 22 Apr 2020.
Metadata
- Authors
- Haase, C. L., Lopes, S., Olsen, A. H., Satylganova, A., Schnecke, V., & McEwan, P.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Corresponding author
- Haase, Christiane Lundegaard
- Venue
- International Journal of Obesity
- Published
- 2021-03-03
- Volume
- 45
- Issue
- 6
- Pages
- 1249-1258
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC8159734
- OpenAlex
- W3134938531
- Cited by
- 199
- References
- 32
- Citations by year
- 2026: 19 · 2025: 48 · 2024: 59 · 2023: 38 · 2022: 28 · 2021: 7
- FWCI
- 28.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity and Health Practices
- Keywords
- weight loss, obesity, body mass index, type 2 diabetes, sleep apnea, hypertension, dyslipidemia, chronic kidney disease, asthma, cardiovascular risk factors, primary care
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Female, United Kingdom, Humans, Hypertension, Male, Middle Aged, Obesity, Primary Health Care, Weight Loss, Comorbidity, Databases, Factual, Risk Reduction Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Weight loss and risk reduction of obesity-related outcomes in 0·5 million people: evidence from a UK primary care database. https://app.cochat.ai/papers/10.1038/s41366-021-00788-4
- The paper
- Haase, C. L., Lopes, S., Olsen, A. H., Satylganova, A., Schnecke, V., & McEwan, P. (2021). Weight loss and risk reduction of obesity-related outcomes in 0·5 million people: evidence from a UK primary care database. International Journal of Obesity. https://doi.org/10.1038/s41366-021-00788-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.